Shandong improve pharmaceutical r&d force people to spend less

On June 21, 2016

Source: qilu evening news

Author: Fan Jia

Attract the public attention of the health reform has been more than half in the past, which become the focus of public opinion in addition to the fee increases, and the high and low prices. The problem of high drug prices has been a highly public criticism. Increasing domestic pharmaceutical, medical equipment innovation research and development ability, help to crack this health problem. We will increase support policy and funding, cutting processes of project application, strengthening clinical and scientific research interaction, improving the capacity of pharmaceutical research and development in our province. The current revision of the regulations on the shandong province to promote transformation of scientific and technological achievements have putted on the agenda.

Take 400000 anti-infection, illness under control

"I most afraid of her infection, an infection using anti-infection imported drugs, expenses cannot predict, may spend hundreds of thousands of disease control." Mention a fiancee anti-infection treatment before, Zhu Xiaoxin still concerned. In February, who lives in village of heze Wu Zhuang Ma Xiuyun was diagnosed with leukemia, hospitalization, her future husband always in the side.

Zhu Xiaoxin, treatment with a few months, are now spent 20560 thousand, there are hundreds of left and right is the import medicines cannot submit an expense account. Zhu Xiaoxin calculated brushstroke zhang, Ma Xiuyun hospitalized 76 days for the first time, in addition to match detection cost, total spent more than 310000, more than 90% of them are medical expenses, these expenses reimbursement only more than 100000. The second hospital spent more than 40000, only for the more than 18000, in general, the proportion of reimbursement accounts for only about thirty percent.

Zhu Xiaoxin, said in the leukemia treatment, chemotherapy cost is only a little head, a course of chemotherapy for three to seven days, with other nutrition medicine, each course is over 10000. But fight infection is a bottomless pit, not only use the imported drugs are very expensive, and do not know when can control the illness, can be stopped. Zhu Xiaoxin said: "the last thousand or so, we spent anti-infection thought a lot of, is really lucky to have a roommate said 400000 there is no control of the disease."

Some time ago, Ma Xiuyun infection after a high fever, anxious Zhu Xiaoxin. At first the doctor to use homebred penicillin and cephalosporin, basic control condition. "The best imported drugs to help, must want to change." Zhu Xiaoxin said, resistance to fungal infection of mika net gave more than 20 days a check bills, spent more than 70000. "I didn't expect so expensive, but didn't also the way." He sighed.

Ma Xiuyun eat another kind of antifungal drugs voriconazole, a grain will be 390 yuan, had 18 grain, spent 7000 multivariate. Zhu Xiaoxin had hoped that through other ways to save part of expenses for medicine, he also heard that some of the imported drugs can act as purchasing agency of generic drugs in India and other countries, prices are much cheaper. "It's a pity that can't buy in China." Zhu Xiaoxin very helpless.

Grasped the nettle, research and development of domestic drugs

Ma Xiuyun also used a recovery in the treatment of white blood cell quantity drugs new red white, each needle 1700 yuan. The price of this benefit from medicine, independent research and development of the technology in China. More than a decade ago, the domestic patients want to inject drugs that increase white blood cell, can only choose the United States or Japan products. In the 1990 s, grasped the nettle of qilu pharmaceutical research team, successfully developed the Chinese own ascension drug white blood cells, recombinant human granulocyte stimulating factor injection and injection with recombinant human interleukin - 11. The two products on the indicators are with foreign branded drug medicine quality, even higher than the original drug, but the price is much lower than the imported drugs.

Later recombinant human granulocyte stimulating factor injection is developed by foreign long-term preparations, an injection of RMB ten thousand yuan of above, there are very few patients use at home. In order to make the domestic patients with high quality and low price, better drug curative effect, qilu pharmaceutical began to develop effective new white. On August 26, 2015, new red white won the state food and drug administration bureau. The product quality, efficacy and imported products, but the price is only one over ten of the latter.

Promote Chinese medicine research and development ability, can give people save a lot of money. Rock l biological technology co., LTD., jinan, chairman of XingZhiQing that: "take the successful development of stents weigao group, its biggest contribution is not a year to weihai pay several hundred million tax, but broke the foreign monopoly, pull down the price of imported stents, this is the biggest contribution to the society."

It is understood that the stents in patients with heart disease use, the past has been to abroad a few medicine monopoly enterprise, for many patients with borrowed for products. The heart stents of weigao group development not only nearly half lower than foreign products, the quality is also very good, quickly edging out the imported stents artificially high monopoly profits.

More than ten years research and development, will be successful

Pharmaceutical innovation is of great significance to people, but at present our country the number of innovative medicine is much less than generic drugs.

Jinan central hospital pharmacy pharmacist Cao Ruimin introduction, deputy director of the imported drugs in the hospital now account for about 5% - 8%, especially in medicine for the treatment of cancer is more dependent on imports. Imported drugs has decreased in recent years, however, because of generic drugs increase gradually, some foreign medicine no protection, domestic has been copied.

Cao Ruimin think although generic drugs, but to make technical and foreign still has a gap, such as penicillin, abroad is no longer need a skin test, but the domestic still need to implement a skin test, although the process is same, but the purity reach.

"Generic drug innovation is much easier than, but really didn't how much to home, ten grade can have one or two." Jinan pan l biological technology co., LTD., chairman of XingZhiQing said, some people go to India now act as purchasing agency generics, because India less strict examination and approval, as long as the efficacy, clinical detection is very loose. But China's strict censorship is to pass clinical inspection strictly, this also is very be necessary.

"Compared with generic drugs, the innovation of the Chinese medicine cycle longer, high technical requirements, some need more than ten years research and development, will be successful." XingZhiQing is introduced, an innovative drug must be at least after the third phase of clinical trial, midway through any link is likely to fail, it is great for drug companies.

To this, China holding group co., LTD. Director Ding Zhenbo feel the same way. Ding Zhenbo said, shandong xinhua pharmaceutical co., LTD. More than 5000 each year on research and development cost, but still not enough. Provincial leaders and relevant departments have advice, hope China holdings group can integrate the entire province pharmaceutical r&d platform, based on the two drug firms, the general research and development institutions in jinan, this things for four or five years, basic don't move. Stems mainly from only by the enterprise itself into difficult to support. Research and development of pharmaceutical research and development industry has a characteristic, ten may be only a success, the platform to build bad not to also do not leave the talent, at present mainly suffer from the magnitude of the supporting policy is too small.

The implementation of incentive policies, inspire scientific research enthusiasm

In the pharmaceutical research and development, lack of funding is many pharmaceutical companies are faced with the problem.

"Jinan to innovative talents of scientific research funds less than the south, and with more rigid." Jinan high-tech zone a drug firms, jinan distribution of talent funds is not at all. In 500000 that a talent funds, for example, generally the first step before 150000, the second step according to hiring employees, pay insurance, realize profits, such as index, the number of money to make the second step. The head also said that apply for talent funding procedure is very complicated, there are many barriers, many didn't take the whole enterprise four or five years, and need to submit materials themselves up.

Of clinical medicine research and development to have the effect of accurate calibration direction, but the current our country research and medical series is separated. I save a 3 armour hospital dean said, at present the hospital just got medical expenses, there is no teaching, scientific research funds. "While our country's medical innovation mainly depends on 3 armour hospital and special hospital crack problems, such as AIDS, cancer, etc."

The dean said, after doctors found scientific research problem, must let him get rid of all clinical multifarious work, problems with scientific research, you must give him the head, which is classified as research series. But in our country, without the scientific establishment in clinic.

China holding group co., LTD. Director Ding Zhenbo think it's important to improve the scientific research personnel enthusiasm, although the law of the People's Republic of China to promote scientific and technological achievements conversion, results, after the production of three to five years in a row, a certain proportion can be extracted into profit incentives r&d staff. But drug approval is a gradual process, introduced the basic sell three to five years is not good, wait for three to five years later, the medicine more profit, but can not implement the incentive policy, is not conducive to stimulate the enthusiasm of medical scientific research personnel.

The reporter understands from the provincial department of science, the current revision of the regulations on the shandong province to promote transformation of scientific and technological achievements have putted on the plan. Main basis in October last year a new revision of the law of the People's Republic of China to promote scientific and technological achievements conversion, and the year of the implementation of "promote the conversion of scientific and technological achievements of the People's Republic of China > several regulations, action plan for promoting transformation of scientific and technological achievements transfer, the above documents emphasizes on scientific research and talent incentive and multi-channel funding mechanism. The new regulations or will come the end of the year.